Multiplatform Pipeline
Transactions & Partnerships
In November 2023, Bristol Myers Squibb acquired ORM-6151/BMS-986497 at a total deal value of $180 million. ORM-6151/BMS-986497 is a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader initially developed by Orum Therapeutics for the treatment of acute myeloid leukemia (AML) and other CD33-expressing malignancies.
In July 2024, Orum entered a multi-target license and option agreement with Vertex Pharmaceuticals. Vertex will use Orum’s TPD² technology for the discovery of novel targeted conditioning agents for use with gene editing and has the right to take up to three options.
Partnering with Orum
Are you interested in any of our pipeline assets or have targets and antibodies that might work well with our GSPT1 degrader or Cbl-b inhibitor payloads? Or have you developed degraders that need a better therapeutic index via antibody delivery?
Orum is ready to discuss a variety of different collaboration possibilities across our TPD² and TPS² platforms and programs.
Please contact us and let us know how we can work together.
Meet the Orum Business Development Team at:
ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit 2024
BIO Europe Fall 2024
ASH 2024